• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2016-2020 年俄罗斯联邦急性冠脉综合征的血运重建。

Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016-2020.

机构信息

National Medical Research Center of Surgery named after A. Vishnevsky, Moscow, Russia.

National Medical Research Center of Cardiology, Moscow, Russia Institution of the Higher Education "A.I. Yevdokimov Moscow State University of Medicine and Dentistry", Moscow, Russia.

出版信息

Kardiologiia. 2021 Dec 31;61(12):4-15. doi: 10.18087/cardio.2021.12.n1879.

DOI:10.18087/cardio.2021.12.n1879
PMID:35057716
Abstract

Aim    To analyze the number of cases of acute coronary syndrome (ACS) [ST segment elevation myocardial infarction (STEMI), non-ST elevation acute coronary syndrome (nSTEACS)] and results of myocardial revascularization for ACS as a part of the monitoring performed by the Ministry of Health Care of Russia*. This analysis allows, on one hand, providing control of morbidity and mortality of patients with socially significant pathologies and, on the other hand, monitoring the effectivity of treatments to identify and correct their shortcomings. Time-related changes in results of myocardial revascularization performed for ACS patients in the Russian Federation in 2020 were analyzed and compared with the values of 2016-2019 based on data of the Russian Ministry of Health Care monitoring.Material and methods    Yearly absolute, relative, and calculated indices of revascularization for ACS were analyzed and compared based on data of the Russian Ministry of Health Care monitoring in 2016-2020.Results    In the Russian Federation in 2020, the lowest number of hospitalizations for ACS (403, 931) was recorded with an unprecedented ratio of 1 / 1.8 for STEMI/nSTEACS, respectively. In Russia in 2020, the proportion of primary percutaneous coronary interventions (pPCI) for STEMI continued growing; it reached 44% and peaked to the maximum for 2016-2020. At the same time, the thrombolytic therapy (TLT) remained essential in the structure of reperfusion strategies during those years (24.0-27.3 % of all STEMI cases). Total death rate of admitted patients with STEMI in Russia was stable at the level of 13.1-14.6 %. In 2020, there were no significant differences in quality indexes of the treatment for STEMI from the previous period (2016-2019). A yearly relative increase in the number of PCIs for STEACS (from 16 % in 2016 to 30 % in 2020 and from 30% to 46% for high-risk nSTEACS) was observed. In 2020, a significant increase in death rate was observed for nSTEACS as a whole (to 4.1 %) and for individual subgroups (high-risk nSTEACS, to 4.5 %; after PCI for nSTEACS, to 1.8 %; and after PCI for high-risk nSTEACS, to 2.8 %) whereas mean death rate values in these subgroups in 2016-2019 were 2.75 %, 3.45 %, 1.5 %, and 2.3 %, respectively.Conclusion    The analysis of revascularization indexes in ACS patients based on the Ministry of Health Care of Russia monitoring performed in 2016-2020 showed a number of positive trends, including an increase in the total number of revascularization procedures; a decrease in the time from the disease onset to the endovascular treatment; an increase in the availability of stenting for severe ACS; and general stabilization of the mortality. On the other hand, the Russian Federation is considerably behind European countries in several qualitative and quantitative parameters of health care in ACS, such as pPCI availability, symptom-to-balloon time, total mortality of all hospitalized STEMI patients, and revascularization for nSTEACS. Despite the gradual improvement of relative quantitative indexes of myocardial revascularization for ACS, negative changes in the absolute number of myocardial revascularizations for various forms of ACS and a notable increase in the death rate in nSTEACS were observed in 2020, including patients after PCI. There is no doubt that the negative results of myocardial revascularization in Russia in 2020 were due to the effect of the COVID-19 pandemic.* monitoring of measures to reduce the mortality from ischemic heart disease (letters of the Ministry of Health Care of the Russian Federation of 13.03.2015 # 17-6 /10 / 1-177 and of 24.07.2015 # 17-9 / 10 / 2-4128), which includes monthly collection of data on the Federal Research Institute for Health Organization and Informatics portal, the Automated System for Monitoring of Medical Statistics, at http://asmms.mednet.ru.

摘要

目的 分析俄罗斯卫生部保健监测中的急性冠状动脉综合征(ACS)[ST 段抬高心肌梗死(STEMI)、非 ST 段抬高急性冠状动脉综合征(nSTEACS)]病例数和 ACS 血运重建结果,并以此作为监测的一部分。这种分析一方面可以控制具有社会重要性的疾病的发病率和死亡率,另一方面可以监测治疗效果,以发现并纠正其不足之处。 方法 分析 2020 年俄罗斯联邦 ACS 患者血运重建的结果,并与 2016-2019 年的数据进行比较,这些数据来自俄罗斯卫生部保健监测。 结果 在俄罗斯联邦,2020 年记录的 ACS 住院人数(403931 例)为历史最低水平,STEMI/nSTEACS 的比例分别为 1/1.8,前所未有。2020 年,俄罗斯经皮冠状动脉介入治疗(pPCI)在 STEMI 中的比例继续增长,达到 44%,达到 2016-2020 年的最高水平。与此同时,溶栓治疗(TLT)在这些年的再灌注策略结构中仍然是必不可少的(所有 STEMI 病例的 24.0-27.3%)。俄罗斯 STEMI 住院患者的总死亡率保持在 13.1-14.6%的稳定水平。2020 年,STEMI 治疗的质量指标与前一时期(2016-2019 年)没有显著差异。STEACS 的 PCI 数量逐年相对增加(从 2016 年的 16%增加到 2020 年的 30%,高危 nSTEACS 从 30%增加到 46%)。2020 年,nSTEACS 整体死亡率(增加到 4.1%)和个别亚组(高危 nSTEACS,增加到 4.5%;nSTEACS 后 PCI,增加到 1.8%;高危 nSTEACS 后 PCI,增加到 2.8%)均有所增加,而这些亚组在 2016-2019 年的平均死亡率分别为 2.75%、3.45%、1.5%和 2.3%。 结论 基于 2016-2020 年俄罗斯卫生部保健监测的 ACS 患者血运重建指标分析显示出一些积极趋势,包括血运重建手术总数的增加;从发病到血管内治疗的时间缩短;严重 ACS 支架的可用性增加;以及死亡率的普遍稳定。另一方面,俄罗斯在 ACS 医疗保健的几个定性和定量参数方面与欧洲国家相去甚远,例如 pPCI 的可用性、症状至球囊时间、所有 STEMI 住院患者的总死亡率以及 nSTEACS 的血运重建。尽管 ACS 血运重建的相对定量指标逐渐改善,但 2020 年各种形式的 ACS 的血运重建绝对数量以及 nSTEACS 死亡率的显著增加(包括 PCI 后患者)仍存在负面变化。毫无疑问,2020 年俄罗斯 ACS 血运重建的负面结果是由于 COVID-19 大流行的影响。

相似文献

1
Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016-2020.2016-2020 年俄罗斯联邦急性冠脉综合征的血运重建。
Kardiologiia. 2021 Dec 31;61(12):4-15. doi: 10.18087/cardio.2021.12.n1879.
2
[Organization of medical care for patients with non-ST-segment elevation acute coronary syndrome in regional vascular centers and primary vascular units in 2009-2012 (according to the data of the ACS register)].2009 - 2012年区域血管中心和基层血管单位非ST段抬高型急性冠状动脉综合征患者的医疗护理组织情况(根据急性冠状动脉综合征登记数据)
Ter Arkh. 2013;85(12):4-8.
3
Immediate versus deferred percutaneous coronary intervention for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials.即刻与延迟经皮冠状动脉介入治疗急性冠状动脉综合征患者的Meta 分析:随机对照试验研究。
PLoS One. 2020 Jul 2;15(7):e0234655. doi: 10.1371/journal.pone.0234655. eCollection 2020.
4
[Features of the Reperfusion Therapy for ST-Segment Elevation Myocardial Infarction According to the Russian Registry of Acute Myocardial Infarction - REGION-IM].[根据俄罗斯急性心肌梗死注册研究-REGION-IM的ST段抬高型心肌梗死再灌注治疗特点]
Kardiologiia. 2024 Feb 29;64(2):3-17. doi: 10.18087/cardio.2024.2.n2601.
5
The incidence and outcomes of high-risk acute coronary syndromes in the Western Cape Province of South Africa: a prospective cohort study.南非西开普省高危急性冠状动脉综合征的发病率和转归:一项前瞻性队列研究。
S Afr Med J. 2023 Apr 4;113(4):24-25.
6
The incidence and outcomes of high-risk acute coronary syndromes in Western Cape Province, South Africa: A prospective cohort study.南非西开普省高危急性冠状动脉综合征的发病情况和结局:一项前瞻性队列研究。
S Afr Med J. 2023 Apr 12;113(5):25-29. doi: 10.7196/SAMJ.2023.v113i5.16764.
7
Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS.急性冠状动脉综合征中钙化病变血管经皮冠状动脉介入治疗后的缺血结局。HORIZONS-AMI(急性心肌梗死中血管重建和支架与优化药物治疗的比较)和 ACUITY(急性冠状动脉介入治疗即刻危险分层及早期介入策略)试验的汇总分析。
J Am Coll Cardiol. 2014 May 13;63(18):1845-54. doi: 10.1016/j.jacc.2014.01.034. Epub 2014 Feb 19.
8
Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.氮化钛氧化物涂层支架与依维莫司洗脱支架治疗ST段抬高型心肌梗死与非ST段抬高型急性冠状动脉综合征的疗效:来自BASE-ACS试验的见解。
Minerva Cardioangiol. 2013 Apr;61(2):201-9.
9
Impact of the COVID-19 pandemic on acute coronary syndromes.COVID-19 大流行对急性冠状动脉综合征的影响。
Swiss Med Wkly. 2020 Dec 31;150:w20448. doi: 10.4414/smw.2020.20448. eCollection 2020 Dec 14.
10
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England.COVID-19 大流行与英格兰急性冠状动脉综合征的入院率及治疗管理。
Lancet. 2020 Aug 8;396(10248):381-389. doi: 10.1016/S0140-6736(20)31356-8. Epub 2020 Jul 14.

引用本文的文献

1
Non-ischemic phenotypes of low-risk chest pain patients based on exercise stress echocardiography: a pilot study.基于运动负荷超声心动图的低风险胸痛患者的非缺血性表型:一项初步研究。
Front Cardiovasc Med. 2025 Feb 19;12:1429449. doi: 10.3389/fcvm.2025.1429449. eCollection 2025.
2
Prediction of Hospital Mortality in Patients with ST Segment Elevation Myocardial Infarction: Evolution of Risk Measurement Techniques and Assessment of Their Effectiveness (Review).ST段抬高型心肌梗死患者医院死亡率的预测:风险测量技术的演变及其有效性评估(综述)
Sovrem Tekhnologii Med. 2024;16(4):61-72. doi: 10.17691/stm2024.16.4.07. Epub 2024 Aug 30.